Grifols (NASDAQ:GRFS – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday, Zacks.com reports. According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and […]
Grifols (NASDAQ:GRFS – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous […]
Zacks Investment Research upgraded shares of Grifols (NASDAQ:GRFS – Get Rating) from a sell rating to a hold rating in a report issued on Friday morning, Zacks.com reports. According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic […]
Morgan Stanley began coverage on shares of Grifols (NASDAQ:GRFS – Get Rating) in a report issued on Friday morning, The Fly reports. The brokerage issued an equal weight rating on the biotechnology company’s stock. A number of other brokerages also recently issued reports on GRFS. StockNews.com began coverage on Grifols in a research report on […]
Grifols (NASDAQ:GRFS – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports. According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, […]